Article Details
Retrieved on: 2024-01-19 17:07:45
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article describes the NVX-CoV2515 vaccine's stronger neutralizing response to the Omicron variant compared to the original NVX-CoV2373, maintaining a consistent safety profile following mRNA vaccines. Biotech developments and COVID-19 vaccine efficacy remain central themes.
Article found on: www.hematologyadvisor.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here